Delivery Order SPE2DB22D2214-SPE2DB26FS2NN
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $19,164.60 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 26, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary pharmaceutical distribution...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This non-competitive, firm fixed-price delivery order is valued at $116,800.12 and is due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL on June 3, 2025, with performance in Conshohocken, Pennsylvania. This is a firm fixed price, non-set-aside contract with a completion date of June 4, 2025. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order valued at $13,438.22 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, non-set-aside contract with a completion date of May 13, 2025, one day after the award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $8,082.22 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of HUMIRA (Adalimumab) prefilled pens at 40 mg/0.4 mL. This is a non-set-aside competitive award with an ultimate completion date of October 28, 2025, with performance to occur at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $36,425.77 delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40mg/4ml (2 units) under a firm fixed price contract. This delivery order, issued on October 27, 2025, with an ultimate completion date of November 24, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been selected to fulfill this medical supply...
- The Defense Logistics Agency awarded a $6,596.59 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL concentration. This is a non-set-aside contract with an ultimate completion date of October 22, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $2,152.36 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This competitively awarded, firm fixed-price contract was issued on June 2, 2025, with an ultimate completion date of June 3, 2025. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $3,054.51 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL pharmaceutical supply. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $3,021.20 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL. This is a firm fixed-price contract with no set-aside designation, executed on June 3, 2025, with an ultimate completion date of June 4, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB26FS2NNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,532.85 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This is a firm fixed-price, non-competitive delivery order awarded on October 29, 2025, with completion expected by October 30, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which serves as a comprehensive pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor supplying medications and medical supplies to military and veteran healthcare systems. The SPE2DX contract enables the company to distribute a broad range of pharmaceutical products across multiple therapeutic domains to support Defense Health Agency requirements and other government healthcare systems globally. HUMIRA, a widely used biologic immunosuppressant medication, represents the type of specialty pharmaceutical product routinely procured through this vehicle to support military medicine operations and beneficiary care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.5k | 10/29/25 |